Demegen develops natural and novel peptides for the treatment or prevention of infections due to multi-drug resistant bacteria and fungi. The Company's lead products address important unmet medical needs. Applications under development include dermatological, vaginal, respiratory, ophthalmic and oral diseases.
The Company holds or has license rights to nineteen issued United States patents, plus many foreign counterparts. These include composition of matter protection on over fifty compounds. Demegen's product development is accomplished through collaborations or licenses with corporate, university and government researchers.